Therapeutic Potential of Resveratrol Through Ferroptosis Modulation: Insights and Future Directions in Disease Therapeutics

Overview

Journal Front Pharmacol

Date 2024 Oct 10

PMID 39386035

Authors

Liu Peng

Xi-Zhuo Hu

Zhi-Qiang Liu

Wen-Kai Liu

Qun Huang

Yue Wen

Affiliations

Soon will be listed here.

Abstract

Resveratrol, a naturally occurring polyphenolic compound, has captivated the scientific community with its promising therapeutic potential across a spectrum of diseases. This review explores the complex role of resveratrol in modulating ferroptosis, a newly identified form of programmed cell death, and its potential implications for managing cardiovascular and cerebrovascular disorders, cancer, and other conditions. Ferroptosis is intricately linked to the pathogenesis of diverse diseases, with resveratrol exerting multifaceted effects on this process. It mitigates ferroptosis by modulating lipid peroxidation, iron accumulation, and engaging with specific cellular receptors, thereby manifesting profound therapeutic benefits in cardiovascular and cerebrovascular conditions, as well as oncological settings. Moreover, resveratrol's capacity to either suppress or induce ferroptosis through the modulation of signaling pathways, including Sirt1 and Nrf2, unveils novel therapeutic avenues. Despite resveratrol's limited bioavailability, advancements in molecular modification and drug delivery optimization have amplified its clinical utility. Future investigations are poised to unravel the comprehensive mechanisms underpinning resveratrol's action and expand its therapeutic repertoire. We hope this review could furnish a detailed and novel insight into the exploration of resveratrol in the regulation of ferroptosis and its therapeutic prospects.

References

Howells L, Berry D, Elliott P, Jacobson E, Hoffmann E, Hegarty B . Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases--safety, pharmacokinetics, and pharmacodynamics. Cancer Prev Res (Phila). 2011; 4(9):1419-25. PMC: 3173869. DOI: 10.1158/1940-6207.CAPR-11-0148. View

Li M, Xie L, Jiang H, Huang Q, Tong R, Li X . Role of Licochalcone A in Potential Pharmacological Therapy: A Review. Front Pharmacol. 2022; 13:878776. PMC: 9168596. DOI: 10.3389/fphar.2022.878776. View

Rauf A, Imran M, Butt M, Nadeem M, Peters D, Mubarak M . Resveratrol as an anti-cancer agent: A review. Crit Rev Food Sci Nutr. 2016; 58(9):1428-1447. DOI: 10.1080/10408398.2016.1263597. View

Blagov A, Markin A, Bogatyreva A, Tolstik T, Sukhorukov V, Orekhov A . The Role of Macrophages in the Pathogenesis of Atherosclerosis. Cells. 2023; 12(4). PMC: 9954519. DOI: 10.3390/cells12040522. View

Ni C, Ye Q, Mi X, Jiao D, Zhang S, Cheng R . Resveratrol inhibits ferroptosis via activating NRF2/GPX4 pathway in mice with spinal cord injury. Microsc Res Tech. 2023; 86(10):1378-1390. DOI: 10.1002/jemt.24335. View

Jiang L, Kon N, Li T, Wang S, Su T, Hibshoosh H . Ferroptosis as a p53-mediated activity during tumour suppression. Nature. 2015; 520(7545):57-62. PMC: 4455927. DOI: 10.1038/nature14344. View

Zhu X, Deng Z, Cao Y, Zhou Z, Sun W, Liu C . Resveratrol prevents Drp1-mediated mitochondrial fission in the diabetic kidney through the PDE4D/PKA pathway. Phytother Res. 2023; 37(12):5916-5931. DOI: 10.1002/ptr.8004. View

Li Y, Ran Q, Duan Q, Jin J, Wang Y, Yu L . 7-Dehydrocholesterol dictates ferroptosis sensitivity. Nature. 2024; 626(7998):411-418. PMC: 11298758. DOI: 10.1038/s41586-023-06983-9. View

Wang X, Simayi A, Fu J, Zhao X, Xu G . Resveratrol mediates the miR-149/HMGB1 axis and regulates the ferroptosis pathway to protect myocardium in endotoxemia mice. Am J Physiol Endocrinol Metab. 2022; 323(1):E21-E32. DOI: 10.1152/ajpendo.00227.2021. View

10.

Lee J, Kim W, Bae K, Lee S, Lee E . Lipid Metabolism and Ferroptosis. Biology (Basel). 2021; 10(3). PMC: 8000263. DOI: 10.3390/biology10030184. View

11.

Xu K, Chang X, Bai X, Liu H, Chen X, Chen H . Activation of Nrf2 inhibits ferroptosis and protects against oxaliplatin-induced ototoxicity. Biomed Pharmacother. 2023; 165:115248. DOI: 10.1016/j.biopha.2023.115248. View

12.

Ren B, Kwah M, Liu C, Ma Z, Shanmugam M, Ding L . Resveratrol for cancer therapy: Challenges and future perspectives. Cancer Lett. 2021; 515:63-72. DOI: 10.1016/j.canlet.2021.05.001. View

13.

Fang X, Zhang J, Li Y, Song Y, Yu Y, Cai Z . Malic Enzyme 1 as a Novel Anti-Ferroptotic Regulator in Hepatic Ischemia/Reperfusion Injury. Adv Sci (Weinh). 2023; 10(13):e2205436. PMC: 10161122. DOI: 10.1002/advs.202205436. View

14.

Zordoky B, Robertson I, Dyck J . Preclinical and clinical evidence for the role of resveratrol in the treatment of cardiovascular diseases. Biochim Biophys Acta. 2014; 1852(6):1155-77. DOI: 10.1016/j.bbadis.2014.10.016. View

15.

Li Y, Huang Z, Pan S, Feng Y, He H, Cheng S . Resveratrol Alleviates Diabetic Periodontitis-Induced Alveolar Osteocyte Ferroptosis Possibly via Regulation of SLC7A11/GPX4. Nutrients. 2023; 15(9). PMC: 10181281. DOI: 10.3390/nu15092115. View

16.

Nie A, Shen C, Zhou Z, Wang J, Sun B, Zhu C . Ferroptosis: Potential opportunities for natural products in cancer therapy. Phytother Res. 2023; 38(3):1173-1190. DOI: 10.1002/ptr.8088. View

17.

Liu Y, Lu S, Wu L, Yang L, Yang L, Wang J . The diversified role of mitochondria in ferroptosis in cancer. Cell Death Dis. 2023; 14(8):519. PMC: 10425449. DOI: 10.1038/s41419-023-06045-y. View

18.

Wang R, Yuan W, Li L, Lu F, Zhang L, Gong H . Resveratrol ameliorates muscle atrophy in chronic kidney disease via the axis of SIRT1/FoxO1. Phytother Res. 2022; 36(8):3265-3275. DOI: 10.1002/ptr.7499. View

19.

Ma Y, Qian Y, Chen Y, Ruan X, Peng X, Sun Y . Resveratrol modulates the inflammatory response in hPDLSCs via the NRF2/HO-1 and NF-κB pathways and promotes osteogenic differentiation. J Periodontal Res. 2023; 59(1):162-173. DOI: 10.1111/jre.13200. View

20.

Mohammadipoor N, Shafiee F, Rostami A, Kahrizi M, Soleimanpour H, Ghodsi M . Resveratrol supplementation efficiently improves endothelial health: A systematic review and meta-analysis of randomized controlled trials. Phytother Res. 2022; 36(9):3529-3539. DOI: 10.1002/ptr.7562. View